Precision Biologics, Inc. announces new US Patent filing on optimized antibody PB-233
Precision Biologics announces the filing of a new patent for our second asset, PB-233. This...
23Sep
01Sep
Precision Biologics announces publication of a new review article in Expert Review of Vaccines, September 1st, 2024.
Precision Biologics announces that a review, entitled "Generation of the therapeutic monoclonal antibody NEO-201, derived...
06Aug
Dr. Philip M. Arlen to Chair and Present at Cambridge Healthtech Institute Immuno-Oncology Summit 2024, August 7-9, 2024, Philadelphia, PA
Precision Biologics’ CEO, Dr. Philip M. Arlen, to Chair Therapeutic Cancer Vaccine Program, and lead...
01Aug
Genetic Engineering and Biotechnology News (GEN) news article highlights Precision Biologics, Inc., August 1, 2024 Issue
Genetic Engineering and Biotechnology News (GEN) news article highlights Precision Biologics, Inc., August 1, 2024...
22Jul
Precision Biologics Awarded New Patent on NEO-201 for Treg Depletion
Precision Biologics awarded new US Patent on its lead monoclonal antibody NEO-201 for regulatory T-cell...
31May
Precision Biologics to present at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting
Precision Biologics presents new data from ongoing clinical trial combining NEO-201 with pembrolizumab at the...
29Apr
PRECISION BIOLOGICS TO PRESENT AT 7th INTERNATIONAL NEOANTIGEN SUMMIT, AMSTERDAM, NETHERLANDS, APRIL 29 – May 1, 2024
7th INTERNATIONAL NEOANTIGEN SUMMIT, AMSTERDAM, NETHERLANDS, APRIL 29 - May 1, 2024 Accelerating Robust, Durable &...
25Apr
PRECISION BIOLOGICS TO PRESENT AT IMMUNO 2024, LONDON, UK, APRIL 25 – 26, 2024
IMMUNO 2024, LONDON, UK, APRIL 25 - 26, 2024 Day 1: Track 1: Discovery & Development:...
15Apr
Read more...
05Apr
American Association for Cancer Research (AACR) 2024 Annual Meeting, April 8, 2024, San Diego, CA, San Diego Convention Center
Precision Biologics will present recent scientific data at the American Association for Cancer Research (AACR)...